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This work aimed to develop a delivery system for treating soft tissue infections for: (1) reducing the released antimicrobial
amount, preventing drug-related systemic side effects, (2) re-discovering the beneficial effects of naturally-derived agents, and (3)
preserving the substrate biomimetic properties. For the first time the potential of Manuka Honey (MH) as a natural antimicrobial
polyelectrolyte, in order to develop nano-structured multilayered coatings for improving antibacterial properties of biomimetic
electrospun meshes, was investigated.
The electrostatic interaction between MH and poly-(allylamine hydrochloride) was demonstrated by QCM analysis, which showed
the successful deposition of MH starting from the third bi-layer. Furthermore, AFM indicated that the resultant concentration vs
coverage response was indicative of an absorption isotherm, as well as being subject to LbL growth once the initial absorption
site has taken hold.
We also confirmed that the MH functionalised membranes were cytocompatible and promoted the attachment and proliferation of
three different cell lines. Moreover, we demonstrated that the antimicrobial MH activity was dependent on both concentrations
used and bacterial strains. Overall, we proved that Manuka Honey can be considered an effective antibacterial agent to









The use of antibiotics has been the cornerstone to prevent bacterial infections; however, the emergency of antibiotic resistant
bacteria is still an open challenge. This work aimed to develop a delivery system for treating soft tissue infections for: (1) reducing
the released antimicrobial amount, preventing drug-related systemic side effects, (2) re-discovering the beneficial effects of
naturally-derived agents, and (3) preserving the substrate functional properties. For the first time Manuka honey (MH) was
proposed as polyelectrolyte within the layer‐by‐layer (LbL) assembly. Biomimetic electrospun poly(ε‐caprolactone) meshes were
treated via LbL assembly to obtain a multilayered nanocoating, consisting of MH as polyanion and poly-(allylamine-hydrochloride) as
polycation. Physico-chemical characterisation demonstrated the successful nano-coating formation. Different cell lines (Human
immortalized and primary skin fibroblasts, and primary endothelial cells) confirmed positively the membranes cytocompatibility,
while bacterial tests using Gram-negative and Gram-positive bacteria demonstrated the antimicrobial MH activity was dependent
on the concentration used and strains tested.
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Abstract 21 
The use of antibiotics has been the cornerstone to prevent bacterial infections; however, the 22 
emergency of antibiotic resistant bacteria is still an open challenge. This work aimed to develop a 23 
delivery system for treating soft tissue infections for: (1) reducing the released antimicrobial amount, 24 
preventing drug-related systemic side effects, (2) re-discovering the beneficial effects of naturally-25 
derived agents, and (3) preserving the substrate functional properties. For the first time Manuka 26 
honey (MH) was proposed as polyelectrolyte within the layer-by-layer (LbL) assembly. Biomimetic 27 
electrospun poly(ε-caprolactone) meshes were treated via LbL assembly to obtain a multilayered 28 
nanocoating, consisting of MH as polyanion and poly-(allylamine-hydrochloride) as polycation. 29 
Physico-chemical characterisation demonstrated the successful nano-coating formation. Different cell 30 
lines (Human immortalized and primary skin fibroblasts, and primary endothelial cells) confirmed 31 
positively the membranes cytocompatibility, while bacterial tests using Gram-negative and Gram-32 
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positive bacteria demonstrated the antimicrobial MH activity was dependent on the concentration 33 
used and strains tested. 34 
1 Introduction 35 
Skin and soft tissue infections (SSTIs) are the most common bacterial infections, encompassing a 36 
variety of pathological conditions that involve skin and underlying subcutaneous tissue, fascia, and 37 
muscles (1). In the US alone, they account for ~10% of hospital admissions, and they are the most 38 
significant cause of morbidity and mortality among hospitalized patients, posing considerable 39 
diagnostic and therapeutic challenges (2). Moreover, the ageing population and the higher number of 40 
critically ill patients are playing a crucial role on the incidence of SSTIs, which have increased 41 
meaningfully over the past two decades (3). The antibiotics has been the cornerstone to prevent 42 
bacterial infections. However, several drawbacks, associated with their adoption, have posed serious 43 
issues towards their efficacy: i) bacterial resistance following the release of each new drug, ii) lack of 44 
wide spectrum action, and iii) reduced function because of the biofilm layers formed by some 45 
bacteria (4, 5). For minimizing SSTIs consequences, including the huge financial burden they cause 46 
onto the healthcare services and the significant societal costs (6), the development of novel and more 47 
effective antimicrobial strategies has revealed of paramount importance. Many studies report the 48 
importance to inhibit the growth of bacteria in the early biofilm formation stage, thus preventing the 49 
infection from starting (7). In this regards, the use of technologies at the nanoscale, to develop 50 
antibacterial surfaces and coatings, has received great attention within the scientific community, as 51 
promising frontier to reduce SSTIs (8). 52 
Among the nanotechnologies Layer-by-layer (LbL) electrostatic assembly provides to develop 53 
multilayered nano-coatings, based on the alternating exposure of a charged substrate to solutions of 54 
positively and negatively charged polyelectrolytes (PEs), where a rinsing step is generally included in 55 
order to prevent cross-contamination of the PE solutions. LbL method is an inexpensive and 56 
environmentally-friendly, versatile and simple technique that allows to achieve desired properties and 57 
fine control of the coating thicknesses by adjusting the deposition cycle conditions (9). Furthermore, 58 
being electrostatic interaction the driving force of LbL assembly, almost any type of charged specie 59 
(eg. organic molecules or biological macromolecules) can be incorporated into any LbL-treated 60 
surfaces (eg. sheets, fibers, etc) (10, 11). Within this study, the authors demonstrated that the main 61 
advantage of LbL assembly was the relatively small amount of loaded biomolecules/drugs needed to 62 
achieve effective concentrations. This has been reported in previous works, where meshes were 63 
functionalised with LbL assembly in order to impart a cascade of nano-stimuli and to control the 64 
adhesion, proliferation and differentiation of stem cells with the consequent formation of new bone 65 
matrix (12) as well as to effectively deliver the metronidazole drug from oral implant (13). 66 
Numerous antibiotic-based coatings, constructed via the LbL assembly technique and intended for 67 
the development of antibacterial implants, have been investigated so far, given the long-acting 68 
stability of LbL film surfaces in comparison to other functionalisation techniques (14, 15). However, 69 
it has been found that the effect of antibiotics may decrease with time, since antibiotic resistant 70 
bacteria may potentially develop (16). Therefore, the emergency of antibiotic resistant bacteria 71 
remains a big challenge also with the use of LbL assembly method. As an alternative, heavy metals, 72 
such as iron, silver, copper, have been considered as promising PEs for multilayer assembly (17, 18). 73 
However, their high loading has been shown to cause tissue toxicity and impaired wound healing 74 
(19) and bacteria may develop a resistance to metal-based nanoparticles as reported for the silver 75 
(20). Moreover, the incorporation of antibacterial peptides and enzymes has also emerged as 76 
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interesting approach for SSTIs (8), but their lack of stability during the LbL preparation has limited 77 
their application (20). 78 
In the last decade, the antimicrobial activity of different natural compounds has been reported in the 79 
literature. As example, chitosan is a well-known biomaterial, obtained from the deacetylation of 80 
chitin, produced from the exoskeleton of arthropods, that possesses hemostatic, antioxidant, 81 
antitumoral and bactericidal behaviour (21). Furthermore, oregano, a worldwide used culinary herb, 82 
showed antimicrobial and antioxidant properties due to the presence of thymol and flavonoids 83 
respectively (22). An alternative natural-based agent, the honey, was proposed in this work in the 84 
virtue of its ancient antibacterial properties. Honey has been used to treat infected wounds by 85 
indigenous cultures around the globe before bacteria were discovered to be the cause of infections 86 
(23). Although some honey varieties have demonstrated to have beneficial effects into infected sites, 87 
most modern research has focused on a particular type produced in New Zealand from the nectar of 88 
the Leptospermum Scoparium shrub, called Manuka honey (MH) (24). This honey contains the 89 
constituents of other honey varieties, but its unique component, methylglyoxal, acts as an additional 90 
antibacterial agent (25). 91 
The increasing prevalence of data supporting honey’s effectiveness as a natural broad-band 92 
antibacterial agent has encouraged researchers in exploring MH as a wound treatment (26) or 93 
incorporated in tissue-engineered hydrogels (27), demonstrating that MH could significantly reduce 94 
the rate of infections on biomaterials, promote fibroblast migration and collagen deposition. In 95 
addition, MH could enhance tissue-material integration/regeneration and accelerate healing of the 96 
surrounding site (24). However, the undesirable cytotoxic effects of high concentrations of honey and 97 
its uncontrolled release over time represent two of the greatest hurdles in the development of honey-98 
containing tissue-like substitutes (28). The LbL-assembly approach allows the incorporation of MH 99 
with a subsequent and more efficient controlled release of honey from the nano-layers. This strategy 100 
offers solutions to the current warning about the potential toxic effects of high honey concentration 101 
on myofibroblasts and local mesenchymal-stem cells (29). Moreover, the main advantage of this 102 
approach is the relatively small amount of honey loaded to achieve a therapeutic outcome, preventing 103 
both bacteria resistance and drug-related systemic side effects. 104 
In this work nano-structured honey-based coatings were deposited on biomimetic electrospun poly(ε-105 
caprolactone) meshes via LbL technique, to obtain discrete nanoscale layers to incorporate and to 106 
control the MH release with minimal interaction with the biomaterial substrate. After the LbL 107 
optimisation for achieving appropriate MH release kinetics, the nano-coating was characterised by 108 
morphological and physico-chemical analyses to evaluate the multi-layered deposition, while by 109 
biological and antibacterial behaviour to study the MH efficiency. 110 
2 Materials and methods 111 
2.1 Materials 112 
Poly(ε-caprolactone) (PCL; Mw =82 kDa), poly(sodium4-styrenesulfonate) (PSS; Mw =70 kDa), 113 
1,6-hexanediamine (ED), chloroform (≥99.9 %), formic acid (≥95 %) and sodium acetate buffer 114 
solution were purchased from Sigma-Aldrich, UK. Poly(allylamine hydrochloride) (PAH) was 115 
supplied from Alfa Aesar, UK, while Medical grade Manuka honey (400 mg/kg of MGO) was 116 
purchased from ManukaGuard®, US. Ultrapure water was obtained by a Milli-Q® Integral system 117 
(Merck, Italy). All materials and chemicals were used without further purification. 118 
2.2 Electrospun membranes preparation 119 
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PCL membranes were fabricated using an electrospinning system (Linari Engineering Srl, Italy). 120 
Process and solution parameters were optimized to fabricate defect-free nanofibers with dimensions 121 
in the hundreds of nanometers scale. Briefly, PCL pellets were solubilized using a chloroform and 122 
formic acid solution (70/30 v/v) to obtain a 12% w/v concentration of the PCL solution. For each 123 
membrane, 0.6 g of PCL were solubilized in 3.5 ml of chloroform for 1 hour under stirring and, then, 124 
1.5 ml of formic acid were added and mixed for 20 minutes. The spinning process was performed at 125 
room temperature and the spinning parameters were set as voltage of 20 kV, syringe flow rate of 1.5 126 
ml/h, and nozzle-collector distance 20 cm. 127 
2.3 Electrospun membranes functionalisation 128 
PCL electrospun membranes (size 10×10 cm and thickness ≈200 µm) were aminolyzed by dipping 129 
into ED solution (0.06 g/mL) for 10 min at 20 ⁰C, in order to graft -NH2- to get a positive charge on 130 
the surface, and then abundantly washed in deionised water and left drying for 24 h. PSS (5 mg/ml), 131 
PAH (5 mg/ml) and MH (15, 30, 60 and 120 mg/ml) solutions were prepared by dissolving the 132 
polyelectrolytes in sodium acetate buffer solution (pH 5.3-5.5). The ζ-potentials of these solutions 133 
was measured by laser Doppler electrophoresis (Zetasizer Nano, Malvern instrument, US). For the 134 
LbL assembly, aminolysed membranes were dipped first into the polyanionic solutions (Manuka 135 
Honey) for 15 min, followed by a washing step in sodium acetate buffer solution for 5 min to remove 136 
any unbound PE material. The membranes were then soaked in the polycationic solution (PAH) for 137 
15 min followed by a washing step using the same conditions described before. This dipping process 138 
was repeated for eight cycles for creating 16 nanolayers. The samples were left to dry overnight, 139 
coded as MH_1.5, MH_3, MH_6 and MH_12 the membranes functionalised by using different 140 
concentration of Manuka Honey (1.5, 3, 6 and 12% w/v respectively) in sodium acetate buffer 141 
solution (pH 5.3-5.5), while the membrane coated with PSS and PAH as PSS/PAH (used as control). 142 
2.4 Physico-chemical characterisation 143 
Quartz Crystal Microbalance Analyses (QCM-D) were performed with a QSense Explorer device 144 
equipped with an open module (Q-Sense, Sweden). Changes in frequency (Δf) and energy dissipation 145 
factor (ΔD) were monitored at its fundamental resonance frequency (5 MHz) and odd overtones (3, 5, 146 
7, 9, 11, 13). Gold coated sensors (QSX301, Q-Sense, Sweden) were used and cleaned following 147 
manufacture’s instruction prior to use. Immediately after cleaning, a gold-coated sensor was placed in 148 
the open module and 400 µl of ED solution were gently poured on the sensor surface using a 149 
micropipette. After 10 minutes the ED solution was removed and 400 µl of sodium acetate buffer 150 
solution were poured to remove non-adhered molecules. Then, the LbL process was reproduced by 151 
alternating MH and PAH solutions to obtain 8-bilayers, following the same procedure described 152 
before. 153 
Morphological analysis of the samples before and after LbL dip assembly was performed by SEM 154 
(Philips XL30-ESEM). Specimens were priory sputtered with a thin layer of gold (~10 nm, sputter 155 
time 40 s at 40 mA). All the images were taken at 20 kV and working distance of 10 mm. 156 
Atomic Force Microscopy (AFM) characterisation was performed with a Bruker Icon AFM with 157 
TESPA-V2 probes in Tapping Mode at 32 0kHz frequency. The fibres were bonded to a metal stub 158 
using two part-epoxy, and the loose fibres above the surface were manually removed to allow probe 159 
access to the well-bonded fibres beneath. 160 
X-ray photoelectron spectroscopy (XPS) was performed with Theta Probe (Thermo Scientific, UK) 161 
equipped with a microfocused AlKa X-ray source (1486.6 eV), operated with a 400 µm spot size 162 
In revi
w
  Running Title 
 
5 
(100 W power). Process parameters were: 200 eV pass energy, 1 eV step size of and of 50 ms dwell 163 
time in not angle-resolved lens mode. Moreover, high resolution spectra were acquired with 40eV 164 
pass energy, 0.1 eV step size and 200 ms as dwell time. Fourier Transform Infrared (FTIR) spectra 165 
were acquired in a wavenumber range of 4000–550 cm-1 using Spectrum Two PE instrument 166 
equipped with a horizontal attenuated total reflectance (ATR) crystal (ZnSe) (PerkinElmer Inc, US; 4 167 
cm-1 resolution and 32 scans). 168 
The amount of Manuka Honey released from the membranes was analysed by in vitro tests after 169 
immersion of 1x1 cm membranes in 1ml of Phosphate Buffer Saline (PBS, Sigma-Aldrich, UK) 170 
solution at 37 °C for different time points (up to 4weeks). The released solution of the soaked 171 
membranes was assayed for glucose (Glucose Assay Kit, Sigma-Aldrich, UK) as proposed by Hixon 172 
(30). 173 
2.5 Cell tests 174 
Membranes with a dimeter of 15 cm were treated with Sudan Black (SB, Sigma-Aldrich, UK) to 175 
avoid the auto-fluorescence of the electrospun membranes: 0.3% (w/v) SB solution was prepared in 176 
70% ethanol and the membranes were immersed in this solution for 15min, and, then, rinsed 3 times 177 
in PBS solution and sterilised under UV light for 30 min (31). 178 
Different cell lines were used to test the membranes cytocompatibility. Human hTERT immortalized 179 
fibroblast from non-malignant myoma (T-HESCs, ATCC, CRL-4003™) were cultured from frozen 180 
stock in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F-12 medium 181 
with 3.1 g/L glucose and 1 mM sodium pyruvate and without phenol red (Sigma-Aldrich, UK) 182 
supplemented with 1.5 g/L sodium bicarbonate, 1%ITS+ Premix (Corning, UK), 500 ng/mL 183 
puromycin, 10% charcoal/dextran treated fetal bovine serum (HyClone, US). Healthy skin human 184 
fibroblasts, kindly donated by Ana Tiganescu at Saint James’s Teaching Hospital in Leeds (isolated 185 
from skin biopsies samples obtained from the Tissue Bank repository) were cultured in 1:1 mixture 186 
of DMEM with high glucose, Glutamax and 10% fetal bovine serum. Finally, primary human 187 
umbilical vein endothelial cells (HUVECs) were isolated from umbilical cord obtained from de-188 
identified term placenta collected from patients who underwent elective caesarean section between 189 
37 and 39 weeks of gestation. After isolation, 95% purity of endothelial cells was observed, validated 190 
morphologically and by immunofluorescent staining for CD31 (DAKO, US) before seeding on the 191 
membranes. Cells were cultured in EBM-2 medium supplemented with EGM-2 Single Quot growth 192 
factors (Lonza, US). All the cell lines were maintained at 37°C in a saturated humidity atmosphere 193 
containing 5% CO2, and they were sub-cultured before reaching 60–70% confluence (approximately 194 
every 2 days) up to passage 5. All the cells were passaged and seeded on the different meshes at 195 
density of 5,000 cells/cm2 (~20,000 cell/well in a 12 well plate). 196 
LIVE/DEAD staining (ReadyProbes® Cell Viability Imaging Kit, Molecular probes) was used 197 
following manufacturer protocols to determine the viability of cells and to check proliferation of cells 198 
exposed for 8 days to medium conditioned with Manuka Honey (1.3% v/v and 8.3% v/v) and on the 199 
different substrates after 8 days in culture. 200 
2.6 Bacterial tests 201 
The Minimum Inhibitory Concentration (MIC) of Manuka honey to Gram-positive S. aureus (ATCC 202 
25923), S. epidermidis (ATCC 12228) and Gram-negative E. coli (ATCC 25922) and P. aeruginosa 203 
(ATCC 10145) was determined according to Wiegand et al. (32). Manuka honey was tested at 204 
concentrations ranging from 3.125 to 500 mg/ml. Bacterial suspensions at the concentration of 5×105 205 
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Colony Forming Units (CFU)/ml were inoculated into Mueller Hinton Broth in absence (control) or 206 
in presence of the different concentrations of honey and the multi-well plates incubated at 37°C for 207 
16-20 h. MIC was identified as the lowest concentration of honey that prevents visible growth of the 208 
tested strains as observed with the unaided eye. Assays were conducted in triplicate and repeated 209 
twice. 210 
The antimicrobial effectiveness of LbL-functionalized electrospun membranes was assessed using 3-211 
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)-based colorimetric assay (33). 212 
Bacterial suspensions at a concentration of 5×105 CFU/ml were prepared in Tryptic Soy Broth 213 
(TSB). Afterwards, 1 ml of each of these suspensions was used to dip all the membranes, previously 214 
sterilized by 30 minutes UV treatment, in 5ml tubes. Samples were incubated at 37 °C for 24 hours at 215 
120 rpm. At the end of the incubation time, bacteria were harvested by centrifugation at 12000rpm 216 
for 10 minutes and incubated for 30 minutes in 1ml of MTT working solution containing 0.03 g of 217 
MTT (Sigma-Aldrich, Italy) in 9.85ml of PBS supplemented with 50 μl of a 20% glucose solution 218 
and 100 μl of a 1 mM menadione solution. Bacteria were then harvested by centrifugation at 12000 219 
rpm for 10 minutes and resuspended in 1 ml of DMSO:glycine 0.1 M pH 10.2 (7:1) buffer. Finally, 220 
absorbance of each sample was measured by spectrophotometric reading at 570 nm wavelength. The 221 
percentage of inhibition of functionalized fibers, compared to PCL fibers (controls), was determined 222 
as [1-(Abstreat/Absctrl)] × 100, where Abstreat indicates optical density of functionalized samples 223 
and Absctrl corresponds to the optical density of controls. 224 
2.7 Statistical analysis 225 
All the experiments were performed at least in triplicate. Results were expressed as a mean ± 226 
standard deviation and statistical significance was calculated using analysis of variance (ANOVA). 227 
The comparison between two means was analysed using Tukey's test with statistical significance 228 
level set at *p<0.05, **p<0.01 and ***p< 0.001. 229 
3 Results 230 
Electrophoresis measurements were performed, showing that MH-based solutions ranging from 1.5% 231 
to 12% w/v were negatively charged with ζ-potentials from -12.6 to -22.4 mV, while PAH solution 232 
was positively charged with a ζ-potential of +14.5 mV. As a control, negatively charge PSS solution 233 
was selected in order to favour complexation due to its strong interaction with PAH. This had a ζ- 234 
potential of -18.8 mV. Furthermore, the evaluation of the electrostatic interaction between MH in 235 
different concentration and PAH was investigated by QCM-D measurements, in order to confirm the 236 
formation of the multilayered structures (34). 237 
As shown in Figure 1, the presence of ED solution caused a shift in both frequency and dissipation 238 
when NH2 groups interacted with the Au surface of the sensor. The subsequent cleaning step 239 
partially removed the layer as confirmed by the increase of Δf values (Δf value after cleaning step ≈ -240 
300 Hz) at around 620 seconds. Then, MH and PAH polyelectrolyte solutions were alternatively 241 
flowed across the positively-charged functionalised Au-crystal for 15 minutes in order to simulate the 242 
LbL dipping conditions of electrospun membranes. The addition of polyelectrolytes molecules on the 243 
crystal surface was confirmed by a cumulative step-wise response of Δf and ΔD, where the black 244 
stars indicated the shift caused by the Manuka Honey-based solutions. The subsequent cleaning step 245 
removed the majority of both polyelectrolytes in the first bi-layers. Starting from the third bi-layer, 246 
the deposition of MH was more evident, particularly for MH_6 and MH_12, while for MH_3 a 247 
significant Δf was observed with the formation of the fourth bi-layer. Furthermore, the ΔD trend 248 
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confirmed the formation of a thicker layer on the top of the Au-crystal as the dissipation factor 249 
increased with time. 250 
The surface morphology of the multilayered coating after LbL assembly was analysed by Scanning 251 
Electron Microscopy (SEM) (Figure 2(A)). The electrospun membranes presented an average fibres 252 
diameter of 0.75 ± 0.22 µm and an intrinsic micro-porosity. After LbL functionalisation, the 253 
membranes coated with MH and PAH appeared smooth and uniform, leading to an increase in the 254 
fiber-diameter, which in turn resulted proportional to the number of bi-layers used. The control 255 
PSS/PAH-coated membranes showed a formation of irregular shaped protuberances, and a 256 
consequently higher surface roughness and fiber diameter in comparison to the bare substrate. 257 
Furthermore, AFM analysis (Figure 2(B)) confirmed the successful functionalisation of the 258 
membranes, and in addition it was possible to visualise the extent of the MH coating in detail using 259 
the tapping mode phase contrast signal. The clean PCL fibres were smooth to a sub-nm level, but in 260 
phase contrast showed striations of 13.5 nm periodicity around the circumference of the fibre 261 
(alternative dark and light stripes of approximately 7 nm width) (Figure 3). 262 
As with SEM, the PSS/PAH showed a thick, irregular and continuous coating. MH 1.5 to 12 w/v % 263 
revealed a clear progression of MH coverage. At 1.5% w/v MH the coating (bright gold vs the darker 264 
brown PCL in Figure 2(B) and 3) forms a quite sparse network across the fibre surface. At 3% MH 265 
the strands of this network have thickened and begin to enclose regions of clean PCL. At 6% MH the 266 
network has fused into an almost continuous coating with a small number of patches of PCL fibre 267 
visible. These remaining patches have almost entirely gone at 12% MH, and a continuous coating has 268 
formed.  269 
The surface coverage of MH visible in the high resolution AFM phase images was analysed by 270 
thresholding to discriminate the coating (Figure 3) and analysing in ImageJ (NIH) using the 271 
histogram function. The resultant concentration vs coverage response (Figure 4(B)) is reminiscent of 272 
an absorption isotherm, and a Langmuir-Freundlich isotherm (35) (allowing for heterogenous and 273 
multi-layer films) was used to fit the film growth, giving an absorption rate constant k = 6.35x10-3 274 
L/g. 275 
Infrared spectroscopy (FTIR-ATR) and X-ray photoelectron (XPS) were performed to analyse the 276 
surface membranes composition before and after LbL assembly. Particularly, the infrared spectra 277 
(Figure 5) revealed the presence of the characteristic chemical bands of the polyelectrolytes used for 278 
coating the PCL electrospun membranes. For the poly(allylamine hydrochloride) the following 279 
chemical bands were observed: νN-H stretching (3360 cm-1); alkyl νC-H stretching (2920 cm-1); N-H 280 
symmetric and asymmetric scissoring vibrations (1490 cm-1 and 1580 cm-1 respectively), and νN-H 281 
asymmetric stretching (1330 cm-1) (9); while the presence of the honey was characterised by different 282 
absorption zones dominated by two water bands at 3300-3400 cm-1 (OH stretch) and 1641 cm-1 (OH 283 
deformation). The band from about 1500–750 cm-1 was related to the most sensitive absorption 284 
region of the honey’s major components; particularly the most suitable region to quantify honey 285 
sugar (59–75%) and organic acids. The small peak at 1110 cm-1 corresponded to stretching of the C–286 
O band of the C–O–C linkage and the peak at around 1690 cm-1 corresponded to C=O stretching 287 
(36). However, all the other honey distinctive peaks were overlapped with the other components of 288 
PCL and PAH. 289 
Figure 6 shows the XPS survey spectra before and after LbL assembly functionalisation. The 290 
surveys showed N1s peak at 399.5 eV, demonstrating PAH was successfully introduced, while C1s at 291 
285 eV and O1s at 630 eV peaks were characteristics of both PAH and Manuka honey. Moreover the 292 
presence of Na1s at 1070 eV and Cl2p at 200 eV was due to the addition of NaCl in the 293 
polyelectrolyte solution for maintaining a stable charge (37). The high resolution spectra for C1s 294 
along with the curve fit showed three peaks attributed to the different Carbon oxidation states: (1) 295 
284.7−285.0, (2) 286.8−287.0, and (3) 288.5−289 eV, corresponding to −C−H or−C−C− bonds, to 296 
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−C−O- bond, and to -C=O groups respectively. It was observed that these components content varied 297 
significantly with the formation of the layers. The concentration of C=O decreased with the 298 
formation of the nanocoating, because it was characteristic of PCL chemical structure. On the other 299 
hand, the component corresponding to C−N bonds increased suggesting the polyelectrolytes coating. 300 
Finally the high resolution spectra for N1s revealed the presence of PAH layers in all the coated 301 
electrospun membranes (no signal present in bare PCL membrane). 302 
The release of glucose was measured over 14 days (Figure 7). The LbL-functionalised membranes 303 
showed three different stages in the release profile as shown for all the samples, where, as expected, 304 
the membrane functionalised with the higher MH content showed the highest glucose released. A 305 
burst release was observed with approximately the 10-12% of MH delivered during the initial 24 306 
hours of incubation (392.6 ± 47.5 µg/ml for MH_12), followed by a controlled and linear MH release 307 
up to 14 days (1.9 ± 0.2 mg/ml for MH_12). At 28 days no significant change in MH release was 308 
noticed for all the samples, probably due to the nanocoating degradation that implied a zero-order 309 
release. 310 
When the effect of medium supplemented with MH was evaluated in respect to MH free medium, the 311 
LIVE/DEAD staining showed 100% viable healthy fibroblasts in all the sample: after staining with 312 
propidium iodide solution, no signal was detected using a standard TRITC/RFP (orange) filter set, 313 
meaning that all the cells had an intact plasma membrane (Figure 8). A slower proliferation, 314 
however, was observed in high concentrated samples, but not significant in comparison to the control 315 
condition. 316 
Then, three different cell types were seeded on all the functionalised electrospun meshes for 8 days. 317 
Before seeding the cells, all the substrates were treated with Sudan Black (SB). This is a quenching 318 
compound commonly used in lipid histochemistry in order to better visualize biological structure. 319 
Using a concentration of 0.3% (w/v) SB in ethanol that was previously proven to be not toxic and to 320 
successfully cancel background fluorescence of polymeric scaffolds (38), it was possible to image the 321 
live and dead cells after 10 days in culture on most of the samples. 322 
Significant differences (p<0.05) were observed only between proliferation on PSS/PAH and MH_6 323 
and MH_12 coated fibers (as shown in Figure 9(A)). The proliferation of fibroblasts on PSS/PAH 324 
sample was lower and statistically different compared to all the other samples. For immortalized 325 
THESC, the proliferation was significantly decreased on PCL samples, while the concentration of 326 
Manuka Honey did not significantly affect the viability. Significant higher proliferation was observed 327 
on PSS/PAH fibers compared to MH_6 coated substrates. Honey coated fibers supported 328 
proliferation of primary endothelial cells with no significant differences depending on the 329 
concentration of honey. Proliferation was significantly lower on PSS/PAH and bare PCL samples 330 
compared to the maximum value obtained on MH_1.5 and MH_3 coated fibers (p<0.05). 331 
Finally, the antibacterial activity of Manuka Honey against both Gram-positive and Gram-negative 332 
species was evaluated by the broth microdilution method. The assay showed a Minimum Inhibitory 333 
Concentration (MIC) at 200 mg/ml (13.6% v/v) for S. aureus and S. epidermidis, at 300 mg/ml 334 
(20.4% v/v) for E. coli and at 500 mg/ml (34% v/v) for P. aeruginosa. The antibacterial activity of 2 335 
mg of each LbL-functionalized electrospun membrane was quantified by means of the MTT assay. 336 
Figure 9(B) shows the differences in the metabolic activity of cells co-incubated for 24h with the 337 
different types of membranes. In comparison with neat PCL membranes, PSS/PAH samples showed 338 
no antibacterial activity. On the other hand, the efficacy of Honey-LbL-functionalised electrospun 339 
membranes depended on the content of Manuka Honey and on the tested strain. Honey-340 
functionalized membranes had no significant efficacy against the Gram-negative species E. coli and 341 
P. aeruginosa (averagely from 1.1% to 11.1% inhibition). Increasing but negligible inhibitions were 342 
observed against S. aureus for MH_1.5, MH_3 and MH_6 samples whereas a significant reduction of 343 
27.2% was detected for MH_12 (p<0.001). For S. epidermidis, significant inhibitory activities of 344 
13.5% for MH_3, of 23.4% for MH_6 and of 34.3% for MH_12 were found (p<0.001). 345 
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4 Discussion 346 
Bacterial resistance to antimicrobial agents is an increasing health and economic problem (39). As an 347 
alternative to antimicrobial drugs, the therapeutic use of ancient remedies has been revaluated in 348 
recent years. Honey is known for its therapeutic potential, including wound healing properties and 349 
antimicrobial activity. Since ancient times, honey has been a traditional remedy of several human 350 
diseases (40). The antibacterial properties of honey are strongly influenced by its high osmolarity, 351 
acidity, content of hydrogen peroxide, and in the specific case of Manuka honey, also by 352 
phytochemical components like methylglyoxal (MGO) and leptosperin (41). However, toxic cellular 353 
effects of the honey-derived agents could potentially limit its clinical use. To date only a few papers 354 
have shown the cytocompatibility of Manuka Honey-based structures for tissue engineering 355 
applications, reporting the correlation of MH concentration with its toxicity to human cells. In this 356 
work, we proposed: (1) Layer-by-Layer assembly as an effective surface functionalisation 357 
technology, and (2) for the first time Manuka Honey as a polyelectrolyte within the LbL assembly 358 
strategy in order to confer antibacterial properties and preserve the cytocompatibility of PCL 359 
electrospun membranes. Among others, electrospinning technology offers the unique opportunity to 360 
develop ECM-like substrates, with biomimetic features, able to enhance soft tissue regeneration. In 361 
addition to this, as demonstrated recently by Gentile et al (9), LbL technology allows the 362 
incorporation of a relatively small amount of loaded drug/biomolecules needed to achieve effective 363 
concentrations for a localised and controlled delivery system without affecting the physico-chemical 364 
properties of the substrate. 365 
Therefore in order to consider MH as a novel polyelectrolyte, electrophoresis measurements were 366 
performed and they showed that MH-based solutions were negatively charged and the MH trend was 367 
in accordance with previous studies, where the ζ-potential was significantly influenced by the 368 
concentration of different studied polysaccharides. Particularly, sodium alginate and k-carrageenan 369 
solutions, considered as weak polyelectrolytes, showed that the increase of the polysaccharide 370 
concentrations lead to more negative ζ-potential values (42). On the other hand, it was reported in 371 
literature that strong polyelectrolytes, such as polyethyleneimine (PEI), were characterised by an 372 
opposite trend, where an increase of the polymer concentration lead to lower ζ-potential values (43). 373 
This indicates that MH acts as a partially-weak polyelectrolyte as the natural-based polyelectrolytes.  374 
A confirmation of the MH potential within LbL functionalisation was provided by QCM-D 375 
measurements, where MH and PAH demonstrated a stable electrostatic complexation with the 376 
tendency of PAH to form a more rigid layer in comparison to MH, as the dissipation factor 377 
underwent a more pronounced shift when MH layer was recorded (44). 378 
Biomimetic fiber-based membranes were produced through electrospinning to mimic the nanofibrous 379 
structure of the native ECM (45). Among other polymers, PCL was selected as former material 380 
thanks to its well know biocompatibility and its stability during LbL processing without 381 
compromising bulk material properties and structure morphology (46). For the optimal 382 
functionalisation conditions of PCL-based electrospun membranes via LbL assembly, the process 383 
parameters were set as follows: a total number of 16 nanolayers, dipping time into the PE solutions of 384 
15 minutes, PAH molar concentration of 0.5 M, in accordance to a previous work reported by the 385 
authors (12). In order to favour the absorption of the first polyelectrolyte, aminolysis treatment was 386 
performed before the LbL assembly functionalisation in order to incorporate primary and secondary 387 
NH2 groups onto the substrate (47). The surface functionalisation did not influence the intrinsic 388 
micro-porosity of the electrospun membranes, which is fundamental for cell penetration, nutrient 389 
transport and waste removal (48), and to make them available biocues of the native ECM (45). 390 
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Particularly SEM showed for the control PSS/PAH-coated membranes a formation of irregular 391 
shaped protuberances, and a consequently higher surface roughness and fiber diameter in comparison 392 
to the bare substrate. This is typical of strong complexation between these two polyelectrolytes and 393 
becomes more evident with an increasing the number of bi-layers, as demonstrated by several studies 394 
(49, 50) . On the other hand, similarly to other natural polyelectrolytes, MH coating appeared smooth 395 
and uniform, leading to an increase in the fiber-diameter, which in turn resulted proportional to the 396 
number of bi-layers used (51, 52). 397 
Although not quantitative, AFM tapping mode phase contrast signal can very clearly differentiate 398 
different material properties, and our work the coating substance showed a reduced phase lag (lighter 399 
in the images) compared with the PCL fibre (darker phase contrast). In phase contrast PCL fibres 400 
showed typical striations (13.5 nm periodicity around the fibre circumference), that are the polymer 401 
crystalline lamellae of the PCL layered between amorphous regions, as observed previously in 100% 402 
PCL fibres with a spacing of 14.8±2.9 nm (53), a value which increased upon addition of another 403 
polymer to the fibre composition. In most partially crystalline polymers these lamellae typically lie in 404 
the range 10-20 nm. They are more visible in the high resolution AFM phase contrast images of the 405 
fibres (for PCL and MH_1.5). Furthermore, AFM indicated that the resultant concentration vs 406 
coverage response was indicative of an absorption isotherm, where the progressive coverage with 407 
concentration indicates that absorption of the partially strong polyelectrolyte to this heterogenous and 408 
porous surface follows a typical surface absorption mechanism, as well as being subject to LbL 409 
growth once the initial absorption site have taken hold. During the LbL process at a given 410 
concentration these sites will gradually thicken and spread out filling in the remaining uncoated 411 
regions (for a cartoon schematic of this mechanism (see Figure 10). 412 
In this work we reported a lower MH-loaded content, comparing with other papers reported in 413 
literature, with a more controlled release in the longer period. Hixon et al. reported a release of 0.5 414 
mg/ml of MH for the first 24 hours, followed by a slight decrease at 4 days and a sustained break 415 
down after 7 days (30). In our work, we demonstrated that LbL assembly can be an effective 416 
methodology for having a controlled release of the natural antibacterial agent within 2 weeks that 417 
represent the period in which most implant-associated infections are initiated (54). 418 
Finally, biological tests demonstrated that MH coating supported proliferation of different cell types 419 
(fibroblasts and endothelial cells) without compromising the biocompatibility of the meshes, while the 420 
antibacterial ones showed that the antimicrobial MH activity was dependent on the concentration used 421 
and the bacteria strain tested. In accordance with our observation, Bucekova et al. (55) demonstrated 422 
that medical-grade Manuka honey was more effective against Gram-positive than Gram-negative 423 
bacteria. Similar results were shown by Tan et al. (56) with MIC95 values of 12.5% (v/v) and 20% (v/v) 424 
for S. aureus and E. coli respectively.  425 
Furthermore, E. coli inhibition was demonstrated by means of the agar diffusion assay for PCL 426 
scaffolds containing 10% and 20% of MH by Minden-Birkenmaier et al. (19). Yang et al. reported 427 
bacterial inhibition rates of different MH/silk ﬁbroin ﬁbrous (SF) matrices (57). In particular, for MH 428 
(10%)/SF, an inhibitory effect ranging from 5% to 10% was detected against S. aureus, E. coli, P. 429 
aeruginosa and MRSA strains. The observed dependence to the bacterial strain might be identified, at 430 
first, in the structural differences of their cell walls. In comparison to Gram-negative strains, in fact, 431 
Gram-positives do not have an outer membrane that offers protection to the peptidoglycan layer from 432 
lysozyme and other antimicrobial agents, making them easier to penetrate and damage (58) . Secondly, 433 
the different grade of susceptibility of bacterial strains might be also due to the different mechanisms 434 
of action involved in MH’s antibacterial activity (59). For example, for S. aureus it was observed that 435 
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MH interferes with the regular cell division process (52). Conversely, for P. aeruginosa it was observed 436 
that inhibitory concentrations cause the loss of cellular integrity, extensive cell lysis and death (60). 437 
Overall, the advantages of the nano-functionalisation strategy described here are marked: (1) to allow 438 
the manufacturing of biomimetic systems with expectable functional properties without 439 
compromising the physico-chemical properties of the electrospun membranes; (2) in vitro release 440 
demonstrated that the MH-loaded meshes were capable of effectively delivering MH in a controlled 441 
way within two-three weeks of incubation; and (3) in vitro tests confirmed the cytocompatibility of 442 
all the proposed MH-based systems while the antibacterial ones showed that the antimicrobial MH 443 
activity was dependent on the concentration used and the bacteria strain tested. This study has 444 
therefore demonstrated that the combination of naturally-derived antibacterial agent with LbL 445 
technique may be applied to the manufacture of medical devices with advanced functionality. 446 
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Figure Captions 465 
Figure 1. Plot of the fifth overtone of Δf (A) and ΔD (B) versus time. Stars indicate events associated 466 
to the dipping step in Manuka Honey solution. 467 
Figure 2. (A) SEM and (B) AFM images of the electrospun membranes before and after LbL assembly 468 
functionalisation. 469 
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Figure 4. (A) High resolution AFM phase contrast images. (B) Analysis of MH coating coverage from 472 
high resolution AFM images. 473 
Figure 5. FTIR-ATR spectra of the electrospun membranes before and after LbL assembly 474 
functionalisation. 475 
Figure 6. XPS survey spectra and high resolution C1s spectra of the electrospun membranes before 476 
and after LbL assembly functionalisation. 477 
Figure 7. Glucose assay for honey detection. 478 
Figure 8. Proliferation of fibroblasts in medium supplemented with Manuka honey at different 479 
concentrations. Blue nuclei staining (NucBlue® Live reagent) of cells cultured in (a) DMEM (control), 480 
(b) DMEM supplemented with Honey 1.3 % v/v, (c) DMEM supplemented with Honey 8.3 % v/v was 481 
detected using a standard DAPI filter. All the picture are recorded with magnification 4x, scale bar 100 482 
mm. 483 
Figure 9. (A) Cell viability of Dermal fibroblasts (i), immortalized THESC (ii) and HUVECs (iii) on 484 
PCL, PSS/PAH, Honey1.5%, 3%, 6%, 12%. * mark significantly different samples. (B) Metabolic 485 
activity measured by MTT assay of 4 different strains incubated for 24h with nano-functionalised 486 
membranes. 487 
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